Medtronic Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Medtronic kazanç ve gelirin sırasıyla yıllık 10.1% ve 4.6% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 10.7% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 15.2% olacağı tahmin edilmektedir.

Anahtar bilgiler

10.1%

Kazanç büyüme oranı

10.7%

EPS büyüme oranı

Medical Equipment kazanç büyümesi	18.3%
Gelir büyüme oranı	4.6%
Gelecekteki özkaynak getirisi	15.2%
Analist kapsamı	Good
Son güncelleme	23 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

BOVESPA:MDTC34 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
4/30/2027	36,904	6,200	7,639	9,294	25
4/30/2026	35,126	5,733	6,857	8,710	32
4/30/2025	33,560	5,274	6,018	7,924	31
10/25/2024	32,996	4,288	5,499	7,195	N/A
7/26/2024	32,577	3,927	5,145	6,898	N/A
4/26/2024	32,364	3,676	5,200	6,787	N/A
1/26/2024	32,320	4,201	4,931	6,470	N/A
10/27/2023	31,958	4,102	4,045	5,570	N/A
7/28/2023	31,558	3,620	4,444	5,831	N/A
4/28/2023	31,227	3,758	4,580	6,039	N/A
1/27/2023	30,771	4,064	4,166	5,636	N/A
10/28/2022	30,806	4,321	4,822	6,290	N/A
7/29/2022	31,070	5,205	5,721	7,137	N/A
4/29/2022	31,686	5,039	5,978	7,346	N/A
1/28/2022	31,785	4,914	5,678	7,034	N/A
10/29/2021	31,798	4,704	5,773	7,162	N/A
7/30/2021	31,597	3,882	5,855	7,254	N/A
4/30/2021	30,117	3,606	4,885	6,240	N/A
1/29/2021	27,926	2,892	4,631	5,945	N/A
10/30/2020	27,868	3,537	4,752	5,996	N/A
7/31/2020	27,927	4,412	4,756	6,002	N/A
4/24/2020	28,913	4,789	6,021	7,234	N/A
1/24/2020	31,062	5,408	6,659	7,871	N/A
10/25/2019	30,891	4,762	6,298	7,519	N/A
7/26/2019	30,666	4,420	5,671	6,815	N/A
4/26/2019	30,557	4,631	5,873	7,007	N/A
1/25/2019	30,555	4,826	4,867	5,958	N/A
10/26/2018	30,378	2,168	4,864	5,905	N/A
7/27/2018	29,947	3,163	N/A	5,649	N/A
4/27/2018	29,953	3,104	N/A	4,684	N/A
1/26/2018	29,725	2,859	N/A	5,419	N/A
10/27/2017	29,639	5,069	N/A	5,502	N/A
7/28/2017	29,934	4,115	N/A	6,067	N/A
4/28/2017	29,710	4,028	N/A	6,880	N/A
1/27/2017	29,361	3,968	N/A	6,433	N/A
10/28/2016	29,012	4,242	N/A	6,145	N/A
7/29/2016	28,725	3,647	N/A	5,952	N/A
4/29/2016	28,833	3,538	N/A	5,218	N/A
1/29/2016	28,435	2,434	N/A	5,804	N/A
10/30/2015	25,819	2,316	N/A	5,774	N/A
7/31/2015	23,127	2,624	N/A	5,408	N/A
4/24/2015	20,261	2,675	N/A	4,902	N/A
1/23/2015	17,410	3,124	N/A	4,318	N/A
10/24/2014	17,255	2,909	N/A	4,163	N/A
7/25/2014	17,083	2,983	N/A	4,286	N/A
4/25/2014	16,893	3,065	N/A	4,959	N/A
1/24/2014	16,879	3,586	N/A	4,901	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: MDTC34 'nin tahmini kazanç büyümesi (yıllık 10.1% ) tasarruf oranının ( 10.4% ) altındadır.

Kazançlar ve Piyasa: MDTC34 şirketinin kazançlarının (yıllık 10.1% ) BR pazarından (yıllık 12.5% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: MDTC34 şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: MDTC34 şirketinin gelirinin (yıllık 4.6% ) BR pazarından (yıllık 7.4% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: MDTC34 şirketinin gelirinin (yıllık 4.6% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: MDTC34 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 15.2 %).

Medtronic Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Medtronic plc Revises Earnings Guidance for the Fiscal Year 2025

Medtronic plc Revises Earnings Guidance for the Fiscal Year 2024

Medtronic plc Raises Earnings Guidance for 2024

Medtronic plc Provides Revenue Results for the Second Half of 2023

Medtronic plc Reiterates Earnings Guidance for the Year 2023

Recent updates

Medtronic plc Receives FDA Clearance for New Inpen App, Pending the Way for Its Smart MDI System Launch with Simplera™? CGM

CMS Grants Transitional Pass-Through Payment for Medtronic Symplicity Spyral Renal Denervation Catheter

Medtronic plc Announces New, Long-Term Data from Its SPYRAL HTN-ON MED Clinical Trial

Medtronic plc Receives FDA Approval of Affera Mapping and Ablation System and Sphere-9 Catheter

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc Announces the Presentation of Clinical Study Results

Medtronic plc Revises Earnings Guidance for the Fiscal Year 2025

Medtronic plc Announces Cash Dividend for Second Quarter of Fiscal Year 2025, Payable on October 11, 2024

Medtronic plc, Annual General Meeting, Oct 17, 2024

Medtronic plc Announces Resignation of Karen Parkhill as CFO

Medtronic plc Announces Retirement of Rob Ten Hoedt as Executive Vice President and President, Global Regions, Effective as of June 28, 2024

Medtronic plc Increases Cash Dividend for the First Quarter of Fiscal Year 2025, Payable on July 12, 2024

Medtronic plc Announces its Investigational OmniaSecure Defibrillation Lead Met its Primary Safety and Effectiveness Endpoints, Existing Safety and Effectiveness Endpoints

Medtronic plc Receives FDA Approval for Inceptiv Closed-Loop Spinal Cord Stimulator

Medtronic plc Announces New Advancements in Artificial Intelligence for Endoscopic Care by Unveiling ColonPRO

Medtronic plc Announces SMART Trial One-Year Data Demonstrates Medtronic Evolut™ Tavr Platform as Optimal Treatment for Severe Aortic Stenosis in Patients with Small Annulus, Which Is Primarily Women

Medtronic plc Presents New Clinical and Real-World Data on the MiniMed™ 780G System from Around the World

Medtronic plc Approves Cash Dividend for the Fourth Quarter of Fiscal Year 2024, Payable on April 12, 2024

Medtronic plc to Report Q3, 2025 Results on Feb 18, 2025

Medtronic plc Announces FDA Approval of Its Percept™? RC Deep Brain Stimulation System

Medtronic Diabetes Announces World's First Approval for MiniMed™ 780G System with Simplera Sync™ Disposable, all-in-one sensor

Medtronic plc Announces FDA Approves the PulseSelect Pulsed Field Ablation System for the Treatment of Both Paroxysmal and Persistent Atrial Fibrillation

Medtronic Announces Cash Dividend for Third Quarter of Fiscal Year 2024, Payable on January 12, 2024

Medtronic plc Revises Earnings Guidance for the Fiscal Year 2024

Medtronic plc Announces Four-Year Results from the Evolut Low Risk Trial

Orchestra BioMed Holdings, Inc Grants FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

Medtronic Issues Statement on the FDA Circulatory Systems Devices Advisory Panel vote for the Symplicity Spyral Renal Denervation System

Medtronic plc Raises Earnings Guidance for 2024

Medtronic plc Approves Cash Dividend for the Second Quarter of Fiscal Year 2024, Payable on October 13, 2023

Medtronic plc Appoints Greg Lewis as New Director

Medtronic plc Presents New Data on MiniMed 780G System on Fixed Meal Dosing and Real-World Time in Range Across Wide Range of Users

Medtronic plc Appoints Ken Washington as Chief Technology and Innovation Officer

Medtronic plc Approves Cash Dividend for the First Quarter of Fiscal Year 2024, Payable on July 14, 2023

Medtronic plc Announces Medtronic Extravascular ICD Global Clinical Trial Results Reinforce Device Safety and Effectiveness

Medtronic Extravascular ICD Global Clinical Trial Results Reinforce Device Safety and Effectiveness

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Medtronic plc to Report Q3, 2024 Results on Feb 20, 2024

Medtronic Linq Insertable Cardiac Monitor Detects 10 Times More Atrial Fibrillation in Ischemic Stroke Patients At Three Years Compared to Standard of Care

Siemens Healthineers, GE Healthcare Studying Potential Deals with Medtronic's Spun Off Units

Medtronic Announces First Patient Enrolled in U.S. Clinical Trial for Hugo™ Robotic-Assisted Surgery System

Medtronic plc Approves Cash Dividend for the Third Quarter of Fiscal Year 2023, Payable on January 13, 2023

Medtronic Completes Enrollment in Pivotal Trial Evaluating First-Of-Its-Kind Pulsed Field Ablation Catheter for Patients with Atrial Fibrillation

Medtronic plc Provides Revenue Results for the Second Half of 2023

Medtronic's SPYRAL HTN-ON MED Study Demonstrates Meaningful Clinical Benefits Consistent with Other SPYRAL HTN Renal Denervation Trials

Medtronic plc Launches of Medtronic Neurovascular Co-Lab Platform to Accelerate Innovation in Stroke Treatment

dorsaVi Partners with Medtronic to Develop New Technology

Medtronic plc Introduces New Program Called My Insights Exclusively Made for Individuals Using MiniMed™ 770G System

Medtronic plc to Receive FDA Approval for Pacing the Heart's Natural Conduction System

Medtronic plc Receives FDA Clearance for Expanded Indication of LINQ II™ Insertable Cardiac Monitor for Use in Pediatric Patients Ages 2 and Older

Medtronic plc Announces SYMPLICITY HTN-3 Trial Data Show Sustained Long-Term Blood Pressure Reductions with Medtronic Renal Denervation Procedure

Kessler Topaz Meltzer & Check, LLP Files Securities Fraud Class Action Lawsuit Against Medtronic plc

Medtronic plc Adapt Study Results Published in the Lancet Diabetes & Endocrinology Show Improved Glycemic Control and Treatment Satisfaction Among Those Using Minimed™ 780G System¹, Compared to Insulin Injections

Medtronic plc (NYSE:MDT) completed the acquisition of remaining 97% stake in Affera, Inc.

Medtronic plc Reiterates Earnings Guidance for the Year 2023

Medtronic plc, Annual General Meeting, Dec 08, 2022

Medtronic plc Approves Cash Dividend for the Second Quarter of Fiscal Year 2023, Payable on October 14, 2022

Medtronic plc Receives FDA Clearance for Next-Generation UNiD Spine Analyzer with Degenerative Spine Surgery Predictive Model

Medtronic plc (NYSE:MDT) completed the acquisition of Left-heart Access Portfolio from Acutus Medical, Inc. (NasdaqGS:AFIB).

Medtronic plc Appoints Lidia Fonseca as an Independent Director

Medtronic plc(NYSE:MDT) dropped from Russell Top 50 Index

Medtronic plc Approves Increase in Ash Dividend for the First Quarter of Fiscal Year 2023, Payable on July 15, 2022

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin